US 12,220,424 B2
Compositions comprising nicotinamide riboside and a urolithin
Penelope Andreux, Eclepens (CH); and Christopher L. Rinsch, Lausanne (CH)
Assigned to Amazentis SA, Lausanne (CH)
Filed by Amazentis SA, Lausanne (CH)
Filed on Oct. 8, 2021, as Appl. No. 17/497,392.
Application 17/497,392 is a continuation of application No. 16/064,922, granted, now 11,166,972, previously published as PCT/EP2016/082596, filed on Dec. 23, 2016.
Claims priority of application No. 1522892 (GB), filed on Dec. 24, 2015; and application No. 1611960 (GB), filed on Jul. 8, 2016.
Prior Publication US 2022/0105117 A1, Apr. 7, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/706 (2006.01); A23L 29/00 (2016.01); A23L 33/10 (2016.01); A61K 9/00 (2006.01); A61K 31/366 (2006.01); A61P 21/00 (2006.01); A61P 25/28 (2006.01)
CPC A61K 31/706 (2013.01) [A23L 29/00 (2016.08); A23L 33/10 (2016.08); A61K 9/0053 (2013.01); A61K 31/366 (2013.01); A61P 21/00 (2018.01); A61P 25/28 (2018.01); A23V 2002/00 (2013.01); A23V 2200/316 (2013.01); A23V 2200/322 (2013.01); A61K 2300/00 (2013.01)] 10 Claims
 
1. A method of improving, maintaining, enhancing, increasing, or promoting mitochondrial function or activity, comprising administering to a subject in need thereof an effective amount of a composition comprising:
a) nicotinamide riboside; and
b) urolithin A or a salt thereof;
wherein the nicotinamide riboside is present in an amount of 20 mg to 5 g; and the urolithin A is present in an amount of 10 mg to 5 g.